Lamellar Biomedical turns its Lamellasome tech to Covid-19

8 April 2020 (Last Updated April 8th, 2020 11:40)

Glasgow-based Lamellar Biomedical has announced the launch of a programme to address the potentially fatal consequences of Covid-19 on respiratory function via its Lamellasome platform.

Lamellasome therapeutics are synthetic anionic lipid vesicles composed of proprietary blends of lipids based on naturally occurring human lamellar bodies. They are synthetically formulated and can be manufactured using standard, scalable industry processes and components, and are ingested through inhalation via nebuliser.

A Lamellasome treatment used in the early stages of a Covid-19 infection could reduce the inflammatory response of acute respiratory distress syndrome (ARDS) seen in patients. In a large animal in‑vivo model of radiation-induced lung injury, inhaled Lamellasome protected lung cells and tissues from injury, pneumonitis and fibrosis at the capillary membrane.